Research Analysts’ Recent Ratings Changes for Aura Biosciences (AURA)

Several brokerages have updated their recommendations and price targets on shares of Aura Biosciences (NASDAQ: AURA) in the last few weeks:

• 10/18/2024 – Aura Biosciences had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 10/18/2024 – Aura Biosciences had its price target raised by analysts at Scotiabank from $20.00 to $23.00. They now have a “sector outperform” rating on the stock.
• 10/18/2024 – Aura Biosciences had its price target raised by analysts at BTIG Research from $21.00 to $24.00. They now have a “buy” rating on the stock.
• 10/18/2024 – Aura Biosciences had its price target raised by analysts at HC Wainwright from $21.00 to $22.00. They now have a “buy” rating on the stock.
• 9/16/2024 – Aura Biosciences was upgraded by analysts at Evercore ISI to a “strong-buy” rating.
• 9/13/2024 – Aura Biosciences had its price target raised by analysts at JMP Securities from $19.00 to $23.00. They now have a “market outperform” rating on the stock.
• 9/13/2024 – Aura Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
• 9/9/2024 – Aura Biosciences was upgraded by analysts at Lifesci Capital to a “strong-buy” rating.
• 8/28/2024 – Aura Biosciences had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $19.00 price target on the stock.

Aura Biosciences Stock Performance

Shares of AURA traded down $0.18 during mid-day trading on Wednesday, reaching $11.21. 3,590 shares of the company’s stock traded hands, compared to its average volume of 175,699. The business’s 50-day moving average price is $8.80 and its 200-day moving average price is $8.13. The stock has a market capitalization of $555.38 million, a P/E ratio of -6.03 and a beta of 0.37. Aura Biosciences, Inc. has a 12 month low of $5.99 and a 12 month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.04. Equities research analysts anticipate that Aura Biosciences, Inc. will post -1.7 EPS for the current year.

Insider Activity at Aura Biosciences

In other Aura Biosciences news, CFO Julie B. Feder sold 25,131 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the sale, the chief financial officer now owns 134,276 shares in the company, valued at $1,615,340.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now owns 121,132 shares of the company’s stock, valued at approximately $1,193,150.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Julie B. Feder sold 25,131 shares of the stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the transaction, the chief financial officer now owns 134,276 shares of the company’s stock, valued at $1,615,340.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 57,506 shares of company stock worth $675,952 over the last ninety days. Company insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AURA. Long Focus Capital Management LLC raised its position in Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after purchasing an additional 561,766 shares during the last quarter. Levin Capital Strategies L.P. raised its position in shares of Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after acquiring an additional 216,266 shares in the last quarter. Regency Capital Management Inc. DE raised its position in shares of Aura Biosciences by 11.4% in the 1st quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock worth $6,163,000 after acquiring an additional 80,162 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Aura Biosciences by 51.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after acquiring an additional 48,549 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Aura Biosciences by 20.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after acquiring an additional 41,711 shares in the last quarter. 96.75% of the stock is owned by institutional investors.

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.